ORAMED PHARMACEUTICALS INC (ORMP) Stock Price, Forecast & Analysis
NASDAQ:ORMP • US68403P2039
ORMP Key Statistics, Chart & Performance
The current stock price of ORMP is 3.46 USD. In the past month the price decreased by -3.62%. In the past year, price increased by 65.55%.
ORMP Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ORMP. When comparing the yearly performance of all stocks, ORMP is one of the better performing stocks in the market, outperforming 90.15% of all stocks.
ORMP Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ORMP. ORMP has a great financial health rating, but its profitability evaluates not so good.
ORMP Financial Highlights
Over the last trailing twelve months ORMP reported a non-GAAP Earnings per Share(EPS) of 1.24. The EPS increased by 726.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2192.6% | ||
| ROA | 19.89% | ||
| ROE | 21.57% | ||
| Debt/Equity | 0 |
ORMP Forecast & Estimates
ORMP Ownership
ORMP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.05 | 1.001T | ||
| JNJ | JOHNSON & JOHNSON | 21.14 | 592.302B | ||
| MRK | MERCK & CO. INC. | 22.9 | 307.324B | ||
| PFE | PFIZER INC | 9.04 | 153.855B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.12 | 124.69B | ||
| ZTS | ZOETIS INC | 18.73 | 55.434B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.75 | 26.247B | ||
| VTRS | VIATRIS INC | 6.35 | 18.371B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.23 | 12.297B | ||
| AXSM | AXSOME THERAPEUTICS INC | 207.52 | 8.81B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ORMP
Company Profile
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Company Info
ORAMED PHARMACEUTICALS INC
1185 Avenue Of The Americas, 3Rd Floor
New York City NEW YORK 10036 US
CEO: Nadav Kidron
Employees: 4
Phone: 16468441164
ORAMED PHARMACEUTICALS INC / ORMP FAQ
What does ORMP do?
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
What is the current price of ORMP stock?
The current stock price of ORMP is 3.46 USD. The price increased by 4.53% in the last trading session.
Does ORAMED PHARMACEUTICALS INC pay dividends?
ORAMED PHARMACEUTICALS INC (ORMP) has a dividend yield of 7.76%. The yearly dividend amount is currently 0.
What is the ChartMill technical and fundamental rating of ORMP stock?
ORMP has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the sector and industry classification for ORAMED PHARMACEUTICALS INC?
ORAMED PHARMACEUTICALS INC (ORMP) operates in the Health Care sector and the Pharmaceuticals industry.
What is the Price/Earnings (PE) ratio of ORAMED PHARMACEUTICALS INC (ORMP)?
The PE ratio for ORAMED PHARMACEUTICALS INC (ORMP) is 2.79. This is based on the reported non-GAAP earnings per share of 1.24 and the current share price of 3.46 USD.
Can you provide the short interest for ORMP stock?
The outstanding short interest for ORAMED PHARMACEUTICALS INC (ORMP) is 2% of its float.